The partnership for our heart indications will likely arise once all pathways to approval are established.
Mesoblast has expressed intentions to meet with the FDA for both congenital heart disease and a pre BLA meeting for the CHF LVAD population for this purpose. It also appears they need to submit the trial protocol for the CHF class 2 & 3 patients.
Once we have clarity on pathways for these indications a partner can be established, hopefully on better terms.
This money gives us funding for the rest of the year to progress all our indications.
Ann: Mesoblast Completes Placement and Entitlement Offer, page-25
-
- There are more pages in this discussion • 130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |